

Richter has submitted an offer and entered into negotiations to acquire certain assets from Mithra Pharmaceuticals in Belgium

Budapest, 3 May 2024 - Gedeon Richter Plc. ("Richter") announces today that it has submitted an offer and entered into negotiations to acquire certain assets from Mithra Pharmaceuticals SA ("Mithra"). Richter confirms that it has participated in the monetisation process of Mithra, which was publicly initiated by Mithra on 5 March 2024. Within the framework of the monetisation process, Richter has submitted an offer, but no binding agreement has been entered into yet. The exclusive negotiations are still ongoing.

Richter - in line with the company's current practice - will announce the details of the transaction if and when all major elements and material details have been negotiated and finalised and the related transaction documentation has been signed.

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 4.3bn (USD 4.7bn) by the end of 2023, Richter's consolidated sales were approximately EUR 2.1bn (USD 2.3bn) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

For further information:

Investors: Róbert Réthy +36 1 431 5680 Media: Zsuzsa Beke +36 1 431 4888